OTCMKTS:ABCZY Abcam - ABCZY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abcam plc Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day Range$19.40▼$19.4052-Week Range N/AVolume5,400 shsAverage Volume4,712 shsMarket Capitalization$3.98 billionP/E RatioN/ADividend Yield0.36%Price TargetN/A ProfileChartCompetitorsHeadlinesShort Interest About Abcam (OTCMKTS:ABCZY) StockAbcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.Read More Receive ABCZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCZY Stock News HeadlinesMarch 30, 2023 | finance.yahoo.comAbcam, plc Publication of 2022 Annual Report and Accounts and Notice of Annual General MeetingFebruary 6, 2023 | msn.comAbcam unveils plaques honouring 41 scientists behind BRCA2 breast cancer gene discoveryApril 1, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. November 9, 2022 | technews.tmcnet.comNanoString and Abcam Expand Collaboration to Advance Spatial Multiomics ResearchOctober 17, 2022 | marketwatch.comAbcam Seeks Approval to Cancel AIM ListingSeptember 29, 2022 | seekingalpha.comAbcam: A Good Growth Stock In The Healthcare MarketSeptember 14, 2022 | seekingalpha.comAbcam ADS Non-GAAP EPS of 14.00p, revenue of £185.2MSeptember 12, 2022 | seekingalpha.comAbcam plc (ABCM) Q4 2022 Earnings Call TranscriptApril 1, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. July 25, 2022 | investing.comAbcam PLC PK (ABCZY)July 20, 2022 | ft.comCambridge biotech Abcam to abandon London listing for NasdaqJuly 1, 2022 | uk.finance.yahoo.comAre analysts upbeat on the outlook for Abcam?March 25, 2022 | tmcnet.comAbcam the most awarded company at 2022 industry awardsMarch 18, 2022 | nasdaq.comWall Street Analysts Predict a 27% Upside in Abcam PLC Sponsored ADR (ABCM): Here's What You Should KnowOctober 27, 2021 | lse.co.ukAbcam completes acquisition of life science research tool distributorAugust 2, 2021 | lse.co.ukAbcam to buy BioVision for $340mAugust 2, 2021 | uk.finance.yahoo.com‘Amazon of antibodies’ Abcam buys up US supplier BioVision in $340million dealAugust 2, 2021 | lse.co.ukAbcam to acquire Boai NKY subsidiary BioVision for USD340 millionAugust 2, 2021 | marketwatch.comAbcam to Buy BioVision for $340 Mln-- Deal DigestAugust 2, 2021 | nasdaq.comAbcam To Buy US-based BioVision For $340 Mln - Quick FactsJuly 1, 2021 | marketwatch.comAbcam Says Underlying Performance Has Been Modestly Ahead of ExpectationsJuly 1, 2021 | lse.co.ukAbcam trades in line with expectations as lab product demand limitedJune 25, 2021 | ca.finance.yahoo.comSome Shareholders May find It Hard To Increase Abcam plc's (LON:ABC) CEO Compensation This YearApril 12, 2021 | finance.yahoo.comAbcam and MEDx extend precision medicine strategic partnershipMarch 4, 2021 | finance.yahoo.comAbcam Expands Presence in China to Support Increased Demand of BioPharma SectorJanuary 29, 2021 | finance.yahoo.comCan You Imagine How Jubilant Abcam's (LON:ABC) Shareholders Feel About Its 164% Share Price Gain?January 11, 2021 | lse.co.ukAbcam Expects Good Interim Results As Most Regions Experience GrowthSee More Headlines Receive ABCZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Industrial Inorganic Chemicals Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ABCZY Previous SymbolNASDAQ:ABCZY CUSIPN/A CIKN/A Webwww.abcam.com Phone44 1223 696 000FaxN/AEmployees1,492Year Founded1998Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$336.37 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares205,080,000Free FloatN/AMarket Cap$3.98 billion OptionableNot Optionable Beta1.29 Social Links Key ExecutivesMr. Alan Thomas Hirzel BS (Age 52)MS, MBA, CEO & Exec. Director Mr. Michael Shaun Baldock (Age 54)CFO & Director Dr. Jonathan Simon Milner (Age 55)Co-Founder & Non-Exec. Deputy Chairman Mr. Mark DermodyInterim CIOJames StaveleyVP of Investor RelationsKey CompetitorsNeogenNASDAQ:NEOGHaemoneticsNYSE:HAEICU MedicalNASDAQ:ICUICerevel TherapeuticsNASDAQ:CERETeladoc HealthNYSE:TDOCView All Competitors ABCZY Stock - Frequently Asked Questions Is Abcam a good dividend stock? Abcam (OTCMKTS:ABCZY) pays an annual dividend of $0.07 per share and currently has a dividend yield of 0.36%. Read our dividend analysis for ABCZY. What is Abcam's stock symbol? Abcam trades on the OTCMKTS under the ticker symbol "ABCZY." How do I buy shares of Abcam? Shares of ABCZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Abcam make? Abcam (OTCMKTS:ABCZY) has a market capitalization of $0.00 and generates $336.37 million in revenue each year. How many employees does Abcam have? The company employs 1,492 workers across the globe. Does Abcam have any subsidiaries? The following companies are subsidiares of Abcam: Abcam (US) Ltd., Abcam Trading (Shanghai) Co. Ltd., Abcam US Group Holdings Inc., and Epitomics Inc.Read More How can I contact Abcam? The official website for the company is www.abcam.com. The company can be reached via phone at 44 1223 696 000. This page (OTCMKTS:ABCZY) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.